Company news

Lotus Pharmaceutical Co., Ltd. news in 2025

Lotus Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Lotus Reports October 2025 Revenue of NT$2,753 Million

November 11, 2025

Lotus Enters License and Supply Agreement with Adalvo for Semaglutide injection

October 6, 2025

Alvogen Announces Sale to Lotus, Creating a Leading International Specialized Generics Platform

September 23, 2025

Lotus Pharmaceutical reports August 2025 Revenue of NT$1,160 Million

September 11, 2025

Lotus reports July 2025 Revenue of NT$2,397 Million

August 12, 2025

Lotus reports June 2025 Revenue of NT$1,044 Million

July 11, 2025

Lotus Announces TFDA Approval for Adcirca for PAH Treatment

February 12, 2025

Lotus Announces the Closing of the Alphachymotrypsine Choay Acquisition, Ready to consolidate revenue from Q1 2025

January 8, 2025

Decks in 2025